57623-78-6

Basic information

• Product Name: N-(4-methoxyphenyl)-2-(phenylamino)benzamide
• Synonyms: N-(4-methoxyphenyl)-2-(phenylamino)benzamide
• CAS NO: 57623-78-6
• Molecular Weight: 318.375
• Mol File: 57623-78-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(4-methoxyphenyl)-2-(phenylamino)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-methoxyphenyl)-2-(phenylamino)benzamide(57623-78-6)
• EPA Substance Registry System: N-(4-methoxyphenyl)-2-(phenylamino)benzamide(57623-78-6)

Safety Data

• Hazardous Substances Data: 57623-78-6(Hazardous Substances Data)

Upstream product

• 35708-19-1 Methyl N-phenylanthranilate 
• 104-94-9 4-methoxy-aniline 
• 108-86-1 bromobenzene 
• 134-20-3 2-carbomethoxyaniline 
• 91-40-7 2-(phenylamino)benzoic acid 

Relevant articles and documents

N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: Synthesis and biological evaluation

Glioblastoma is one of the most lethal brain tumors. The crucial chemotherapy is mainly alkylating agents with modest clinical success. Given this desperate need and inspired by the encouraging results of a phase II trial via concomitant Topo I inhibitor plus COX-2 inhibitor, we designed a series of N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents based on structure modification on 1,5-naphthyridine derivatives (Topo I inhibitors). Notably, the target compounds I-1 (33.61 ± 1.15 μM) and I-8 (45.01 ± 2.37 μM) were confirmed to inhibit COX-2, while a previous reported compound (1,5-naphthyridine derivative) resulted nearly inactive towards COX-2 (IC50 > 150 μM). Besides, I-1 and I-8 exhibited higher anti-proliferation, anti-migration, anti-invasion effects than the parent compound 1,5-naphthyridine derivative, suggesting the success of modification based on the parent. Moreover, I-1 obviously repressed tumor growth in the C6 glioma orthotopic model (TGI = 66.7%) and U87MG xenograft model (TGI = 69.4%). Besides, I-1 downregulated PGE2, VEGF, MMP-9, and STAT3 activation, upregulated E-cadherin in the orthotopic model. More importantly, I-1 showed higher safety than temozolomide and different mechanism from temozolomide in the C6 glioma orthotopic model. All the evidence demonstrated that N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents could be promising for the glioma management.

An advantageous synthesis of new indazolone and pyrazolone derivatives

The synthesis of new indazolone and pyrazolone derivatives starting from methyl anthranilate type substrates is presented. This general approach constitutes a novel and advantageous alternative for the synthesis of the target heterocycles, which implies the use of the environmentally friendly oxidizer PIFA. The synthetic design includes the oxidation of N-arylamides by the hypervalent iodine reagent to the corresponding N-acylnitrenium ions, which can be intramolecularly trapped by an amine moiety to furnish the title compounds by formation of a new N-N single bond.